Logo image of ABEO

ABEONA THERAPEUTICS INC (ABEO) Stock Overview

USA - NASDAQ:ABEO - US00289Y2063 - Common Stock

5.55 USD
+0.07 (+1.28%)
Last: 10/27/2025, 1:14:34 PM

ABEO Key Statistics, Chart & Performance

Key Statistics
Market Cap284.60M
Revenue(TTM)400.00K
Net Income(TTM)57.24M
Shares51.28M
Float45.66M
52 Week High7.54
52 Week Low3.93
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.54
PEN/A
Fwd PE45.34
Earnings (Next)11-17 2025-11-17
IPO1980-09-19
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ABEO short term performance overview.The bars show the price performance of ABEO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15

ABEO long term performance overview.The bars show the price performance of ABEO in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20 30 40

The current stock price of ABEO is 5.55 USD. In the past month the price increased by 0.74%. In the past year, price decreased by -15.69%.

ABEONA THERAPEUTICS INC / ABEO Daily stock chart

ABEO Latest News, Press Relases and Analysis

ABEO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.53 402.71B
AMGN AMGEN INC 13.26 155.74B
GILD GILEAD SCIENCES INC 15.5 148.84B
VRTX VERTEX PHARMACEUTICALS INC 24.87 108.03B
REGN REGENERON PHARMACEUTICALS 12.72 61.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 62.88B
ARGX ARGENX SE - ADR 90.17 51.13B
ONC BEONE MEDICINES LTD-ADR 5.08 34.51B
INSM INSMED INC N/A 34.56B
NTRA NATERA INC N/A 26.46B
BNTX BIONTECH SE-ADR N/A 25.30B
BIIB BIOGEN INC 9.31 21.86B

About ABEO

Company Profile

ABEO logo image Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in Cleveland, Ohio and currently employs 136 full-time employees. The firm's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

Company Info

ABEONA THERAPEUTICS INC

6555 Carnegie Ave, 4th Floor

CLEVELAND OHIO 75219 US

CEO: Michael Amoroso

Employees: 136

ABEO Company Website

ABEO Investor Relations

Phone: 16468134701

ABEONA THERAPEUTICS INC / ABEO FAQ

Can you describe the business of ABEONA THERAPEUTICS INC?

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in Cleveland, Ohio and currently employs 136 full-time employees. The firm's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).


What is the current price of ABEO stock?

The current stock price of ABEO is 5.55 USD. The price increased by 1.28% in the last trading session.


What is the dividend status of ABEONA THERAPEUTICS INC?

ABEO does not pay a dividend.


How is the ChartMill rating for ABEONA THERAPEUTICS INC?

ABEO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the market capitalization of ABEO stock?

ABEONA THERAPEUTICS INC (ABEO) has a market capitalization of 284.60M USD. This makes ABEO a Micro Cap stock.


Can you provide the ownership details for ABEO stock?

You can find the ownership structure of ABEONA THERAPEUTICS INC (ABEO) on the Ownership tab.


ABEO Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ABEO. When comparing the yearly performance of all stocks, ABEO is a bad performer in the overall market: 85.47% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ABEO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ABEO. ABEO has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ABEO Financial Highlights

Over the last trailing twelve months ABEO reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS increased by 30.63% compared to the year before.


Industry RankSector Rank
PM (TTM) 14310.5%
ROA 23.25%
ROE 34.99%
Debt/Equity 0.09
Chartmill High Growth Momentum
EPS Q2Q%-378.95%
Sales Q2Q%N/A
EPS 1Y (TTM)30.63%
Revenue 1Y (TTM)-100%

ABEO Forecast & Estimates

12 analysts have analysed ABEO and the average price target is 20.91 USD. This implies a price increase of 276.76% is expected in the next year compared to the current price of 5.55.

For the next year, analysts expect an EPS growth of 174.57% and a revenue growth 27374.5% for ABEO


Analysts
Analysts86.67
Price Target20.91 (276.76%)
EPS Next Y174.57%
Revenue Next Year27374.5%

ABEO Ownership

Ownership
Inst Owners73.63%
Ins Owners5.63%
Short Float %20.12%
Short Ratio9.9